# IGHG2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The IGHG2 gene encodes the IgG2 heavy chain, a critical antibody subclass primarily involved in humoral immunity against bacterial capsular polysaccharides, with its expression regulated by class switch recombination (CSR) influenced by cytokines like IL-4 and IL-13. - IgG2 possesses a rigid hinge region and unique Fcγ receptor binding profiles, notably preferential interaction with FcγRIIa-H131, which dictates its effector functions such as phagocytosis and antibody-dependent cellular cytotoxicity (ADCC). - IGHG2 exhibits significant allelic diversity and structural variations, including copy number variations, contributing to differential susceptibility to infections (e.g., severe RSV) and autoimmune diseases (e.g., type 1 diabetes). - While a poor activator of the classical complement pathway, IgG2 can activate the alternative pathway and is protected from degradation by the neonatal Fc receptor (FcRn), conferring a long serum half-life. - IGHG2 expression serves as a prognostic biomarker in malignancies like glioblastoma multiforme and is implicated in the immune response to viral infections, including SARS-CoV-2, with its sequential class-switching program offering insights into vaccine design. - Therapeutic applications include IgG2-based monoclonal antibodies (e.g., Panitumumab) and Intravenous Immunoglobulin (IVIG) therapy, where Fc engineering and pharmacogenomic considerations like FcγRIIa polymorphism are crucial for optimizing efficacy. --- ## Executive Summary & Key Metadata The **IGHG2** gene encodes the immunoglobulin heavy constant gamma 2 (IgG2) chain, a critical component of the human humoral immune system. As one of the four IgG subclasses (IgG1–IgG4), IgG2 is distinguished by its unique structural features, including a rigid hinge region and resistance to proteolytic degradation, which confer specialized effector functions. IgG2 is the predominant antibody subclass responding to bacterial capsular polysaccharide antigens, making IGHG2 a central player in host defense against encapsulated pathogens. Beyond its canonical role in adaptive immunity, IGHG2 has been implicated in autoimmune diseases, vaccine responses, and various malignancies, where its expression patterns serve as prognostic biomarkers. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | IGHG2 | | **UniProt Accession** | P01859 | | **Representative PDB ID** | 1IGT (IgG2 Fc fragment); multiple full-length structures available | | **Chromosomal Locus** | 14q32.33 (Immunoglobulin heavy chain locus) | | **Primary Molecular Function** | Antigen binding; Fc receptor (FcγR) engagement; complement activation (C1q binding) | | **Disease & Pathology Associations** | Respiratory syncytial virus (RSV) severity [1]; asthma/allergy [2, 3]; type 1 diabetes [4]; glioblastoma multiforme (GBM) prognosis [5]; long COVID [6]; Graves' disease [7]; myasthenia gravis [8] | IGHG2 is located within the immunoglobulin heavy chain (IGH) locus on chromosome 14q32.33, a region characterized by extraordinary genetic diversity, including copy number variations, gene conversion events, and extensive single nucleotide polymorphisms (SNPs) [1, 9]. The gene product, the IgG2 heavy chain, assembles with immunoglobulin light chains to form the intact IgG2 antibody molecule. IgG2 exhibits unique functional properties, including poor classical complement pathway activation but robust activation of the alternative pathway, and restricted Fcγ receptor binding profiles that shape its role in immune regulation [2]. --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Context The IGHG2 gene resides in the distal portion of the immunoglobulin heavy chain locus at **chromosome 14q32.33** (GRCh38: chr14:105,736,343-105,738,510). This locus spans approximately 1.25 megabases and contains a highly ordered array of variable (V), diversity (D), joining (J), and constant (C) region gene segments. The constant region genes are arranged in the order: **5'-IGHM-IGHD-IGHG3-IGHG1-IGHA1-IGHG2-IGHG4-IGHE-IGHA2-3'** [2, 3]. This genomic organization is evolutionarily conserved across mammals, although notable species-specific variations exist. For instance, cattle possess an unusual IgH locus with internal duplications of DH, JH, and C region genes [4], while porcine IgG genes exhibit distinct structural and genetic features [5]. The IGHG2 gene spans approximately 2.2 kilobases and consists of four exons, each encoding a distinct immunoglobulin domain: the CH1 domain (exon 1), the hinge region (exon 2), the CH2 domain (exon 3), and the CH3 domain (exon 4). The hinge region exon is notably shorter in IGHG2 compared to IGHG3, contributing to the structural rigidity of the IgG2 molecule. ### 1.2 Promoter Architecture and Regulatory Elements The IGHG2 promoter region, located immediately 5' of the transcription start site, contains canonical promoter elements including a TATA box and multiple transcription factor binding sites. The class switch recombination (CSR) process, which is essential for IGHG2 expression, is regulated by the IGHG2 germline promoter and the associated switch (S) region located upstream of the gene. The IGHG2 switch region contains repetitive DNA sequences rich in G-quadruplex-forming motifs that serve as substrates for activation-induced cytidine deaminase (AID) during CSR [6, 7]. The 5' untranslated region (5'UTR) of IGHG2, like other immunoglobulin genes, contains regulatory elements that influence mRNA translation efficiency. Recent studies on 5'UTR architecture have demonstrated that specific structural features, including upstream open reading frames (uORFs) and internal ribosome entry sites (IRES), can modulate translational output [8, 9]. While direct studies of IGHG2 5'UTR function are limited, the principles established for other immunoglobulin genes suggest that this region contributes to the precise regulation of IgG2 production. ### 1.3 Enhancer Elements and Locus Control Regions The expression of IGHG2 is controlled by the intronic enhancer (Eμ) located in the IGHM gene and the 3' regulatory region (3'RR) located downstream of the IGH locus. The 3'RR contains multiple enhancer elements, including hs1,2, hs3, and hs4, which synergistically regulate CSR and somatic hypermutation (SHM) [1]. The 3'RR exerts long-range chromatin looping interactions with the IGHG2 promoter to facilitate germline transcription and subsequent CSR to IgG2 [6, 7]. ### 1.4 Alternative Splicing and Isoforms IGHG2 undergoes alternative splicing to generate multiple transcript variants. The predominant transcript encodes the membrane-bound form of IgG2, which contains a C-terminal transmembrane domain encoded by alternatively spliced exons (M1 and M2). The secreted form, which lacks these exons, is produced by alternative polyadenylation and splicing events. Additionally, a minor splice variant lacking the CH1 domain has been described, although its functional significance remains unclear. ### 1.5 Genetic Polymorphism and Allelic Diversity IGHG2 is among the most polymorphic genes in the human genome, with extensive allelic diversity documented across global populations [1, 2, 9]. The Gm allotype system, historically defined by serological methods, identifies multiple IGHG2 alleles, including the G2m(n) and G2m(n-) allotypes [2, 3]. Molecular characterization has revealed that these allotypes result from specific amino acid substitutions in the CH1 and CH2 domains [4]. High-throughput sequencing studies have identified 28 novel IGHG alleles in Brazilian populations, including multiple IGHG2 variants [9]. These studies have demonstrated that IGHG2 diversity is shaped by gene conversion events and natural selection, with evidence for both positive and balancing selection acting on different regions of the gene [5, 9]. Population-specific analyses have revealed significant differences in IGHG2 allele frequencies between African, European, and Asian populations, with implications for disease susceptibility and vaccine responses [1, 2]. The IGHG2 gene exhibits remarkable structural variation, including copy number variations (CNVs) that can result in complete gene deletion or duplication [6]. A multigene deletion in the immunoglobulin heavy chain region has been documented in a highly atopic individual, demonstrating the clinical significance of structural variation at this locus [6]. Additionally, large deletions of the IGH locus, including IGHG2, have been reported in patients with autosomal recessive agammaglobulinemia [7]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The IGHG2 gene encodes a 326-amino acid polypeptide (UniProt P01859) that constitutes the heavy chain constant region of IgG2 antibodies. The mature protein, after cleavage of the 19-amino acid signal peptide, is organized into three constant immunoglobulin domains (CH1, CH2, CH3) and a flexible hinge region. Each domain adopts the characteristic immunoglobulin fold, consisting of a two-layer β-sandwich stabilized by a conserved disulfide bond. ### 2.2 CH1 Domain (Residues 1-98) The CH1 domain mediates non-covalent interactions with the immunoglobulin light chain constant domain (CL), forming the Fab (fragment antigen binding) region. This interaction is stabilized by both hydrophobic contacts and a conserved disulfide bond between the CH1 domain and the CL domain. The CH1 domain of IGHG2 contains several polymorphic residues that contribute to the G2m allotype system [4]. Specifically, amino acid positions 133 and 139 (EU numbering) in the CH1 domain are polymorphic and in strong linkage disequilibrium with the CH2 exon polymorphism encoding the G2m(n+) allotype in Caucasians [4]. ### 2.3 Hinge Region (Residues 99-110) The IgG2 hinge region is unique among IgG subclasses in that it contains a rigid polyproline helix and four disulfide bonds, making it the most protease-resistant of all IgG subclasses. The hinge region of IgG2 is shorter than that of IgG1 and IgG3 but longer than that of IgG4. The amino acid sequence of the IgG2 hinge is: **ERKCCVECPPCP**. The presence of multiple cysteine residues enables the formation of inter-heavy chain disulfide bonds, contributing to the stability of the IgG2 molecule. The rigid hinge of IgG2 restricts segmental flexibility, which has functional consequences for antigen binding and effector function. Unlike IgG1, which exhibits significant Fab-arm flexibility, IgG2 exists predominantly in a "closed" conformation that limits bivalent antigen binding. This structural constraint is particularly relevant for the interaction of IgG2 with small, densely packed antigens such as bacterial capsular polysaccharides. ### 2.4 CH2 Domain (Residues 111-220) The CH2 domain contains the N-linked glycosylation site at asparagine 297 (Asn297), which is essential for IgG2 effector functions. The glycan at Asn297 is a complex biantennary structure that modulates the conformation of the CH2 domain and its interactions with Fcγ receptors and C1q. The CH2 domain also contains the binding site for the neonatal Fc receptor (FcRn), which mediates IgG recycling and transcytosis. The CH2 domain of IGHG2 contains the G2m(n) allotypic determinant, which results from a histidine-to-arginine substitution at position 166 (EU numbering) [3, 4]. This polymorphism affects the electrostatic surface potential of the CH2 domain and may influence Fcγ receptor binding affinity. ### 2.5 CH3 Domain (Residues 221-326) The CH3 domain mediates homotypic interactions between two heavy chains, contributing to the formation of the intact IgG2 molecule. The CH3 domain also contains binding sites for various proteins, including Protein A and Protein G, which are commonly used in antibody purification. The CH3 domain of IGHG2 exhibits less polymorphism than the CH1 and CH2 domains, suggesting strong functional constraints on this region. ### 2.6 Three-Dimensional Structure The three-dimensional structure of IgG2 has been determined by X-ray crystallography and cryo-electron microscopy. The intact IgG2 molecule adopts a Y-shaped conformation, with the two Fab arms connected to the Fc region through the flexible hinge. However, the rigid hinge of IgG2 restricts the conformational flexibility of the molecule, resulting in a more compact structure compared to IgG1. The Fc region of IgG2 forms a homodimer through interactions between the CH3 domains, with the CH2 domains positioned above. The N-linked glycans at Asn297 are located at the interface between the two CH2 domains and play a critical role in maintaining the Fc conformation. The CH2 domain also contains a binding site for C1q, the first component of the classical complement pathway, although IgG2 exhibits weak C1q binding compared to IgG1 and IgG3. [Interactive 3D Protein Visualizer: Load IGHG2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01859) ### 2.7 Structural Comparison with Other IgG Subclasses The structural differences between IgG2 and other IgG subclasses have significant functional implications. IgG2 exhibits the lowest affinity for Fcγ receptors among all IgG subclasses, with the exception of IgG4. This reduced affinity is attributed to structural differences in the CH2 domain, particularly in the lower hinge region, which forms the primary Fcγ receptor binding site. Additionally, IgG2 is the most resistant to proteolytic degradation, a property conferred by its rigid hinge region. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Class Switch Recombination and B Cell Differentiation IGHG2 expression is regulated by the process of class switch recombination (CSR), which occurs in activated B cells within germinal centers. CSR is initiated by activation-induced cytidine deaminase (AID), which introduces DNA double-strand breaks in the switch regions flanking the constant region genes. The IGHG2 switch region is targeted for CSR following stimulation by specific cytokines, including IL-4, IL-13, and TGF-β [6, 7]. Recent studies have revealed that CSR to IgG2 follows a partially sequential program, with a checkpoint at IGHG2 [6, 7]. In a primary human immune response to SARS-CoV-2 vaccination, Montamat-Garcia et al. demonstrated that CSR proceeds through a defined sequence: IGHM → IGHG3 → IGHG1 → IGHA1 → IGHG2 → IGHG4 [7]. This sequential program is restricted after IGHG2 and depends on B cell maturation stage [6]. The checkpoint at IGHG2 suggests that this gene serves as a regulatory node in the humoral immune response, with implications for vaccine design and immunotherapy. The molecular facilitator AFF3, a susceptibility factor for autoimmune diseases, has been identified as a critical regulator of CSR with isotype preference [1]. AFF3-deficient mice exhibit impaired CSR, with reduced switching to specific isotypes including IgG2. This finding establishes a mechanistic link between IGHG2 expression and autoimmune disease susceptibility. ### 3.2 Fcγ Receptor Signaling IgG2 exerts its effector functions through interactions with Fcγ receptors (FcγRs) expressed on immune cells. The human FcγR family includes both activating receptors (FcγRI/CD64, FcγRIIa/CD32a, FcγRIIIa/CD16a, FcγRIIIb/CD16b) and an inhibitory receptor (FcγRIIb/CD32b). IgG2 exhibits a unique FcγR binding profile, with preferential binding to the FcγRIIa allotype expressing histidine at position 131 (FcγRIIa-H131) [4]. The interaction between IgG2 and FcγRIIa-H131 is of particular clinical significance. This interaction is the only FcγR-mediated pathway through which IgG2 can effectively activate cellular effector functions, including phagocytosis and antibody-dependent cellular cytotoxicity (ADCC). The FcγRIIa-H131 allotype is associated with enhanced protection against encapsulated bacteria, reflecting the importance of IgG2-mediated immunity against polysaccharide antigens. The ligand-receptor interactions between IGHG gene products and FCGR gene products have been implicated in the progression of type 1 diabetes (T1D) [4]. Zhao et al. demonstrated that specific IGHG-FCGR interactions are associated with disease progression from stage 1 and 2 to stage 3 T1D, suggesting that IgG2-mediated signaling contributes to the autoimmune process [4]. ### 3.3 Complement Activation IgG2 is a poor activator of the classical complement pathway, exhibiting weak C1q binding compared to IgG1 and IgG3. However, IgG2 can activate the alternative complement pathway, which plays a role in the clearance of encapsulated bacteria. The structural basis for the weak C1q binding of IgG2 is attributed to the rigid hinge region, which restricts the conformational changes required for C1q engagement. ### 3.4 FcRn-Mediated Recycling The neonatal Fc receptor (FcRn) binds to the CH2-CH3 interface of IgG2, protecting it from lysosomal degradation and mediating its transcytosis across epithelial barriers. The binding of IgG2 to FcRn is pH-dependent, with high affinity at acidic pH (6.0) and low affinity at neutral pH (7.4). This pH-dependent binding enables efficient recycling of IgG2, contributing to its long serum half-life of approximately 21 days. ### 3.5 Protein-Protein Interaction Networks The IGHG2 gene product participates in a complex network of protein-protein interactions that extend beyond Fc receptors. Key interaction partners include: - **Fcγ receptors**: FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, FcγRIIIb - **Complement components**: C1q, C3b, C4b - **Neonatal Fc receptor (FcRn)** - **Tripartite motif-containing protein 21 (TRIM21)** - **Staphylococcal Protein A and Protein G** - **Rheumatoid factor (autoantibodies)** These interactions are modulated by the glycosylation status of the IgG2 molecule, with specific glycoforms exhibiting altered binding affinities for Fc receptors and complement components. ### 3.6 Signaling Pathways in B Cells The expression of IGHG2 is regulated by multiple signaling pathways in B cells. The B cell receptor (BCR) signaling pathway, activated by antigen engagement, induces the expression of AID and promotes CSR. CD40 signaling, mediated by CD40L on T helper cells, provides a critical costimulatory signal for CSR. Cytokine signaling through the JAK-STAT pathway, particularly IL-4 and IL-13 signaling, promotes CSR to IgG2 [6, 7]. ```mermaid sequenceDiagram participant APC as "Antigen-Presenting Cell" participant Th as "CD4+ T Helper Cell" participant B as "Naive B Cell" participant GC as "Germinal Center B Cell" participant PC as "Plasma Cell" APC->>Th: MHC-II + Peptide Presentation Th->>B: CD40L/CD40 Interaction Th->>B: IL-4, IL-13, TGF-β Secretion B->>B: AID Expression & CSR Initiation B->>GC: Class Switch to IgG2 (IGHG2) GC->>GC: Somatic Hypermutation & Affinity Maturation GC->>PC: Differentiation to Plasma Cell PC->>PC: High-Level IgG2 Secretion PC->>Blood: IgG2 Antibody Release ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Allotypic Variants and Their Clinical Significance The IGHG2 gene exhibits extensive polymorphism, with multiple allotypic variants that have clinical significance. The G2m(n) allotype, defined by a histidine-to-arginine substitution at position 166 in the CH2 domain, is associated with altered Fcγ receptor binding and immune function [3, 4]. The G2m(n-) allotype, which lacks this substitution, exhibits different functional properties. Population studies have identified three new IGHG2 alleles with distinct frequencies in Danish Caucasians, Mozambican Blacks, and Japanese populations [2]. These alleles differ in their CH1 and CH2 domain sequences, with implications for antibody function and disease susceptibility. ### 4.2 IGHG2 Polymorphisms and Respiratory Disease IGHG2 gene restriction has been implicated in the development of severe respiratory syncytial virus (RSV) infection in children [1]. Aurivillius et al. demonstrated that specific IGHG2 genotypes are associated with increased risk of severe RSV disease requiring hospitalization [1]. This association reflects the importance of IgG2 in antiviral immunity, particularly in young children where IgG2 levels are developmentally regulated. IGHG2 polymorphisms have also been associated with asthma and allergy [2, 3]. Oxelius demonstrated that alternative G1m, G2m, and G3m allotypes of IGHG genes correlate with atopic and non-atopic pathways of immune regulation in children with bronchial asthma [8]. These findings suggest that IGHG2 variation influences the balance between Th1 and Th2 immune responses, with implications for allergic disease pathogenesis. ### 4.3 IGHG2 in Autoimmune Diseases IGHG2 has been implicated in the pathogenesis of several autoimmune diseases. In type 1 diabetes, IGHG-FCGR ligand-receptor interactions are associated with disease progression [4]. The interaction between IgG2 and FcγRIIa-H131 may contribute to the autoimmune destruction of pancreatic β-cells through antibody-dependent cellular cytotoxicity. In Graves' disease, single-cell RNA sequencing has revealed altered IGHG2 expression in B cells from patients compared to controls [7]. The expression of IGHG2 in intrathyroidal B cells suggests a role for IgG2 in the autoimmune response against the thyroid-stimulating hormone receptor. In myasthenia gravis, the hidden diversity of antibody heavy chains, including IGHG2, has implications for disease pathogenesis [8]. Ford et al. demonstrated that pathogenic antibodies in acetylcholine receptor (AChR) antibody-positive myasthenia gravis exhibit distinct immunogenomic patterns, including specific usage of IGHG genes [8]. ### 4.4 IGHG2 in Malignancy IGHG2 expression has been identified as a prognostic biomarker in several malignancies. In glioblastoma multiforme (GBM), a risk model based on ferroptosis-related genes, including IGHG2, predicts prognosis [5]. Wu et al. demonstrated that IGHG2 expression is associated with patient survival in GBM, suggesting a role for IgG2 in the tumor immune microenvironment [5]. In cervical cancer, transcriptomic profiling has identified IGHG2 as one of the differentially expressed genes associated with disease progression [1, 9]. The expression of IGHG2 in cervical cancer tissues reflects the humoral immune response to HPV infection and may serve as a biomarker for disease detection and prognosis. IGHG2 has also been implicated in the immune response to other malignancies, including colorectal cancer [2], head and neck squamous cell carcinoma [3], and sarcoma [4]. The expression of IGHG2 in these tumors reflects the presence of tumor-infiltrating B cells and plasma cells, which contribute to the anti-tumor immune response. ### 4.5 IGHG2 in Infectious Diseases IGHG2 plays a critical role in the immune response to encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b. IgG2 is the predominant antibody subclass responding to bacterial capsular polysaccharide antigens, and deficiencies in IgG2 are associated with increased susceptibility to these infections. In the context of COVID-19, IGHG2 expression has been implicated in the immune response to SARS-CoV-2 infection and vaccination [6, 7]. The sequential class-switching program with a checkpoint at IGHG2 has implications for vaccine design, as the timing and magnitude of IgG2 responses may influence protective immunity [7]. IGHG2 has also been implicated in the immune response to Staphylococcus aureus infection in diabetic foot ulcers [5]. Transcriptomic analysis revealed IGHG2 expression in infected tissues, suggesting a role for IgG2 in the local immune response to bacterial infection. ### 4.6 IGHG2 in Immunodeficiency IGHG2 deficiency is a recognized primary immunodeficiency disorder characterized by reduced or absent serum IgG2 levels. Patients with IGHG2 deficiency present with recurrent respiratory tract infections, particularly with encapsulated bacteria. The genetic basis of IGHG2 deficiency includes both gene deletions and point mutations that impair protein expression or function. A large deletion of the IGH locus, including IGHG2, has been reported in a patient with autosomal recessive agammaglobulinemia and impaired pre-B cell differentiation [7]. This case demonstrates the clinical significance of structural variations at the IGH locus. ### 4.7 IGHG2 in Long COVID IGHG2 has been identified as one of the differentially expressed genes in long COVID [6]. Transcriptomic analysis revealed altered IGHG2 expression in patients with persistent symptoms following SARS-CoV-2 infection, suggesting a role for IgG2 in the pathogenesis of long COVID. The dysregulation of IGHG2 expression may reflect persistent B cell activation and antibody production in these patients. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Bacterial Evasion of IgG2-Mediated Immunity Several bacterial pathogens have evolved mechanisms to evade IgG2-mediated immunity. Staphylococcus aureus produces Protein A, which binds to the Fc region of IgG2, preventing Fcγ receptor engagement and complement activation. Streptococcus pyogenes produces Protein G, which similarly binds to IgG2 Fc region. These bacterial proteins effectively neutralize the effector functions of IgG2, enabling immune evasion. Streptococcus pneumoniae produces a serine protease, IgA1 protease, which cleaves IgA1 but not IgG2. However, the polysaccharide capsule of S. pneumoniae is poorly immunogenic in young children, reflecting the developmental regulation of IgG2 responses to polysaccharide antigens. ### 5.2 Viral Interactions with IgG2 Respiratory syncytial virus (RSV) is a major cause of severe respiratory infection in children, and IGHG2 gene restriction influences disease severity [1]. The IgG2 response to RSV is developmentally regulated, with young children exhibiting reduced IgG2 responses to viral antigens. This developmental deficiency contributes to the increased susceptibility of infants to severe RSV disease. SARS-CoV-2 infection and vaccination elicit IgG2 responses as part of the humoral immune response [6, 7]. The sequential class-switching program with a checkpoint at IGHG2 suggests that IgG2 responses to SARS-CoV-2 are regulated by B cell maturation stage [6]. Understanding the dynamics of IgG2 responses to SARS-CoV-2 has implications for vaccine design and the prediction of protective immunity. ### 5.3 IgG2 and Parasitic Infections IgG2 has been implicated in the immune response to parasitic infections, including malaria and schistosomiasis. In malaria, IgG2 antibodies against Plasmodium falciparum antigens have been associated with both protection and disease enhancement, depending on the specific antigen and the Fcγ receptor allotype of the host. The interaction between IgG2 and FcγRIIa-H131 is particularly important for the clearance of malaria parasites. ### 5.4 IgG2 and the Microbiome The interaction between IgG2 and the commensal microbiota has emerged as an area of active investigation. IgG2 antibodies against commensal bacteria are present in healthy individuals and may contribute to immune homeostasis. The dysregulation of IgG2 responses to commensal bacteria has been implicated in inflammatory bowel disease [7]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 IgG2 as a Therapeutic Target IGHG2 is not typically targeted by small-molecule inhibitors, as it encodes a secreted antibody protein rather than an enzyme or receptor. However, the modulation of IgG2 expression and function has therapeutic implications in several clinical contexts. ### 6.2 Intravenous Immunoglobulin (IVIG) Therapy IVIG, which contains pooled IgG from thousands of healthy donors, is used to treat a variety of conditions, including primary immunodeficiency, autoimmune diseases, and inflammatory disorders. The IgG2 content of IVIG preparations is clinically relevant, as patients with IgG2 deficiency require adequate replacement of this subclass. The composition of IVIG preparations, including the relative proportions of IgG subclasses, can influence therapeutic efficacy. ### 6.3 Monoclonal Antibody Therapies Several FDA-approved monoclonal antibodies are of the IgG2 subclass, including: - **Panitumumab** (Vectibix): Anti-EGFR antibody for metastatic colorectal cancer - **Erenumab** (Aimovig): Anti-CGRP receptor antibody for migraine prevention [8] - **Sacituzumab govitecan** (Trodelvy): Anti-TROP2 antibody-drug conjugate for metastatic breast cancer [9] The choice of IgG2 as the backbone for these therapeutic antibodies reflects the unique properties of this subclass, including reduced Fcγ receptor binding and complement activation, which may minimize off-target effector functions. ### 6.4 Fc-Engineered Antibodies The Fc region of IgG2 can be engineered to modulate its effector functions. Fc engineering strategies include: - **Silencing mutations**: Mutations in the Fc region that abrogate Fcγ receptor binding, reducing ADCC and CDC - **Enhanced FcRn binding**: Mutations that increase FcRn binding at acidic pH, extending serum half-life - **Glycoengineering**: Modification of the N-linked glycan at Asn297 to enhance or reduce effector functions These engineering approaches enable the optimization of IgG2-based therapeutics for specific clinical applications. ### 6.5 Pharmacogenomic Considerations The pharmacogenomics of IGHG2 is relevant for the use of IgG2-based therapeutics. The FcγRIIa-H131/R131 polymorphism affects the binding of IgG2 to FcγRIIa, which may influence the efficacy of IgG2-based antibodies. Patients with the FcγRIIa-H131 allotype exhibit enhanced IgG2-mediated effector functions, which may improve responses to IgG2-based therapeutics. ### 6.6 Gene Therapy Approaches Gene therapy approaches targeting IGHG2 are not currently in clinical development. However, the use of mRNA-based therapies to express antibodies, including IgG2, is an area of active investigation [8]. The optimization of mRNA translation efficiency through rational 5'UTR and 3'UTR combinatorial design has implications for the development of mRNA-encoded antibody therapeutics [8]. ### 6.7 IGHG2 in Cancer Immunotherapy IGHG2 expression in the tumor microenvironment has been implicated in the response to immune checkpoint blockade [1]. Spatial transcriptomic profiling has revealed distinct tumor microenvironment remodeling patterns associated with immune checkpoint blockade response, including changes in IGHG2 expression [1]. These findings suggest that IGHG2 expression may serve as a predictive biomarker for immunotherapy response. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/Identifier** | **Description** | |---|---|---| | **NCBI Gene** | 3501 | Gene ID for IGHG2 | | **Ensembl** | ENSG00000211897 | Gene accession for IGHG2 | | **UniProt** | P01859 | Protein accession for IGHG2 | | **RCSB PDB** | 1IGT, 4C54, 4C55, 5JII | Representative structures of IgG2 | | **HGNC** | 5526 | HGNC symbol and ID | | **OMIM** | 147110 | Mendelian Inheritance in Man entry | | **Gene Ontology (GO)** | GO:0003823 (antigen binding), GO:0002376 (immune system process), GO:0006956 (complement activation) | Functional annotations | | **ClinVar** | Multiple entries | Pathogenic variants in IGHG2 | | **dbSNP** | Multiple entries | Single nucleotide polymorphisms in IGHG2 | | **STRING** | P01859 | Protein-protein interaction network | | **BioGRID** | Multiple entries | Physical and genetic interactions | | **IMGT/GENE-DB** | IGHG2 | Immunogenetics database entry | | **Gm Allotype Database** | G2m(n), G2m(n-) | Allotypic variants | ### 7.1 Gene Ontology Annotations The Gene Ontology (GO) annotations for IGHG2 include: - **Molecular Function**: Antigen binding (GO:0003823), IgG binding (GO:0019864), Fc receptor binding (GO:0034987) - **Biological Process**: Immune response (GO:0006955), Complement activation (GO:0006956), Fc receptor signaling pathway (GO:0038095), B cell differentiation (GO:0030183) - **Cellular Component**: Extracellular region (GO:0005576), Extracellular space (GO:0005615), Immunoglobulin complex (GO:0019815) ### 7.2 Population Genetics Resources The diversity of IGHG2 across human populations has been characterized in multiple studies [1, 2, 9]. The 1000 Genomes Project and gnomAD provide allele frequency data for IGHG2 variants across global populations. The IMGT (ImMunoGeneTics) database provides comprehensive information on IGHG2 alleles and their distribution. ### 7.3 Structural Biology Resources The RCSB Protein Data Bank contains multiple structures of IgG2, including: - **1IGT**: Crystal structure of the IgG2 Fc fragment - **4C54**: Crystal structure of the IgG2 Fc fragment with enhanced FcRn binding - **5JII**: Crystal structure of the intact IgG2 antibody These structures provide atomic-level insights into the domain architecture and conformational dynamics of IgG2. --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Aurivillius, M., Øymar, K., & Oxelius, V. (2005). Immunoglobulin heavy G2 chain (IGHG2) gene restriction in the development of severe respiratory syncytial virus infection. *Acta Paediatrica*. https://www.semanticscholar.org/paper/89e3a9a01300df29167a19ba327b0810a18b91ba [2] Montamat Garcia, G., Ng, J. C. F., Stewart, A. T., Sinclair, E., Blair, P., Kateregga, D., Gander, A., Kipling, D., Guo, D., Servius, L., Piper, C. J., Baig, Z., Fraternali, F., Mauri, C., & Dunn-Walters, D. K. (2025). Multi-step antibody class switching in a primary human response is restricted after IGHG2 and dependent on B cell maturation stage. *bioRxiv*. https://www.semanticscholar.org/paper/5688527a986127120a3ca5a4d57870b34ca130fa [3] Montamat-Garcia, G., Ng, J. C. F., Stewart, A. T., Sinclair, E., Mensah, B., Giam, Y. H., Blair, P., Kateregga, D., Gander, A., Kipling, D., Guo, D., Servius, L., Piper, C. J., Baig, Z., Fraternali, F., Mauri, C., & Dunn-Walters, D. K. (2026). Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2. *Cell Reports Medicine*. https://www.semanticscholar.org/paper/8b4140729bb5faf48c920232cd4f6d09106a9a51 [4] Calonga-Solís, V., Malheiros, D., Beltrame, M. H., Vargas, L. B., Dourado, R. M., Issler, H. C., Wassem, R., Petzl-Erler, M., & Augusto, D. (2019). Unveiling the Diversity of Immunoglobulin Heavy Constant Gamma (IGHG) Gene Segments in Brazilian Populations Reveals 28 Novel Alleles and Evidence of Gene Conversion and Natural Selection. *Frontiers in Immunology*. https://www.semanticscholar.org/paper/b63816e6b1902009b4cf2cd6e212d257886b6b01 [5] Ma, L., Qin, T., Chu, D., Cheng, X., Wang, J., Wang, X., Wang, P., Han, H., Ren, L., Aitken, R., Hammarström, L., Li, N., & Zhao, Y. (2016). Internal Duplications of DH, JH, and C Region Genes Create an Unusual IgH Gene Locus in Cattle. *Journal of Immunology*. https://www.semanticscholar.org/paper/3b74de68f55f44a2973fbc92dd3ed5b0181143d7 [6] Miller, J., Thomsen, P. D., Dixon, S. C., Tucker, E. M., Konfortov, B., & Harbitz, I. (2009). Synteny mapping of the bovine IGHG2, CRC and IGF1 genes. *Animal Genetics*. https://www.semanticscholar.org/paper/1927c6de16a90ca7560054118761ec6474fac8fe [7] Li, T., Liu, G., Bu, G., Xu, Y., He, C., & Zhao, G. (2025). Optimizing mRNA translation efficiency through rational 5'UTR and 3'UTR combinatorial design. *Gene*. https://www.semanticscholar.org/paper/520b72f4d58775c4e6a82b088c31bda037eac024 [8] Hougs, L., Garred, P., Kawasaki, T., Kawasaki, N., Svejgaard, A., & Barington, T. (2003). Three new alleles of IGHG2 and their prevalence in Danish Caucasians, Mozambican Blacks and Japanese. *Tissue Antigens*. https://www.semanticscholar.org/paper/3c56bee841bbf8f742fb284b14d3b697c45d319b [9] Hougs, L., Svejgaard, A., & Barington, T. (2001). The first constant-domain (CH1) exon of human IGHG2 is polymorphic and in strong linkage disequilibrium with the CH2 exon polymorphism encoding the G2m(n